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Summary
Background.  —  Risk  stratiﬁcation  in  asymptomatic  patients  with  severe  aortic  stenosis  (AS)  is
based on  exercise  test  results.  However,  differentiating  between  pathological  and  physiologi-Asymptomatic  aortic
stenosis;
Abnormal  exercise
test
cal breathlessness  during  exercise  is  sometimes  challenging.  Cardiopulmonary  exercise  testing
(CPET) may  improve  quantiﬁcation  of  cardiopulmonary  exercise  capacity  in  patients  with  valve
diseases.
Aims. —  To  assess  the  ability  of  CPET  to  detect  abnormal  responses  to  exercise  and  a  clinical
endpoint (occurrence  of  European  Society  of  Cardiology  guidelines  surgical  class  I  triggers).
Abbreviations: AET, Abnormal Exercise Test; AS, Aortic Stenosis; AVR, Aortic Valve Replacement; CPET, Cardiopulmonary Exercise Testing;
RER, Respiratory Exchange Ratio; ROC, Receiver Operating Characteristic; VCO2, Carbon Dioxide Output; VE, Ventilation; VO2, Oxygen
Uptake.
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Methods.  —  Forty-three  consecutive  patients  (mean  age  69  ±  13  years;  31  men)  with  no  reported
symptoms  and  severe  AS  (aortic  valve  surface  area  <  1  cm2 or  indexed  aortic  valve  surface  area
≤ 0.6  cm2/m2)  prospectively  underwent  symptom-limited  CPET.
Results. —  Twelve  (28%)  patients  had  an  abnormal  exercise  test  (AET)  with  symptoms  (abnormal
dyspnoea  n  =  11;  angina  n  =  1).  Both  VE/VCO2 slope  >  34  (hazard  ratio  [HR]  =  5.76,  95%  conﬁ-
dence interval  [CI]  1.086—30.587;  P  =  0.04)  and  peak  VO2 ≤  14  mL/kg/min  (HR  6.01,  95%  CI
1.153—31.275;  P  =  0.03)  were  independently  associated  with  an  AET.  Furthermore,  VE/VCO2
slope  >  34  (HR  3.681,  95%  CI  1.318—10.286;  P  =  0.013)  and  peak  VO2 ≤  14  mL/kg/min  (HR  3.058,
95% CI  1.074—8.713;  P  =  0.036)  were  independent  predictors  of  reaching  the  clinical  endpoint.
Conclusions.  —  Cardiopulmonary  exercise  testing  is  a  useful  tool  for  characterizing  breath-
lessness during  an  exercise  test  in  apparently  asymptomatic  patients  with  AS.  Peak
VO2 ≤  14  mL/kg/min  and  VE/VCO2 slope  >  34  were  associated  with  an  AET  and  the  occurrence
of European  Society  of  Cardiology  guideline  surgical  class  I  triggers.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’épreuve  d’effort  en  cas  de  sténose  aortique  serrée  asymptomatique  d’après
l’interrogatoire  vise  à  démasquer  la  survenue  de  symptômes.  Néanmoins,  il  est  parfois  difﬁcile
de différentier  un  essoufﬂement  à  l’effort  pathologique  d’un  essoufﬂement  physiologique.
Objectifs.  —  Évaluer  la  capacité  de  l’épreuve  d’effort  cardiorespiratoire  chez  les  patients
atteints d’une  sténose  aortique  serrée  asymptomatique  d’après  l’interrogatoire  à  (i)  détecter
une réponse  anormale  à  l’effort,  (ii)  à  prédire  un  objectif  clinique  (la  survenue  d’une  indication
opératoire  de  classe  I selon  la  Société  européenne  de  cardiologie).
Méthodes.  —  Une  épreuve  d’effort  cardiorespiratoire  a  été  réalisée  prospectivement  chez
quarante-trois  patients  consécutifs  (d’âge  moyen  69  ±  13  ans  ;  32  hommes)  porteurs  d’une
sténose aortique  serrée  (surface  aortique  <  1  cm2 ou  surface  aortique  indexée  ≤  0,6  cm2/m2)
sans symptôme  rapporté  à  l’interrogatoire.
Résultats.  —  Douze  patients  (28  %)  ont  présenté  des  symptômes  lors  du  test  d’effort  (dyspnée
anormale  n  =  11  ;  angor  n  =  1).  Une  pente  VE/VCO2 >  34  (hazard  ratio  [HR]  5,76,  95  %  intervalle
de conﬁance  [IC]  1,086—30,587  ;  p  =  0,04)  et  un  pic  de  VO2 ≤  14  mL/kg/min  (HR  6,01,  95  %
IC 1,153—31,275  ;  p  =  0,03)  étaient  indépendamment  associés  avec  la  survenue  de  symptômes
lors de  l’épreuve  d’effort.  De  plus,  une  pente  VE/VCO2 >  34  (HR  3,681,  95  %  IC  1,318—10,286  ;
p =  0,013)  et  un  pic  de  VO2 ≤  14  mL/kg/min  (HR  3,058,  95  %  IC  1,074—8,713  ;  p  =  0,036)  étaient
associés  à  une  indication  chirurgicale  de  classe  I.
Conclusions.  — L’épreuve  d’effort  cardiorespiratoire  peut  s’avérer  utile  pour  déﬁnir  le  carac-
tère pathologique  d’une  dyspnée  lors  d’un  test  d’effort  dans  le  cadre  d’une  sténose  aortique
serrée censée  être  asymptomatique  selon  l’interrogatoire.  Un  pic  de  VO2 ≤  14  mL/kg/min  et
une pente  VE/VCO2 >  34  sont  associés  à  la  survenue  de  symptôme  lors  du  test  d’effort  et  à  une
indication  chirurgicale  de  classe  I  de  l’ESC.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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tackground
he  indication  for  aortic  valve  replacement  (AVR)  in  asymp-
omatic  patients  with  aortic  stenosis  (AS)  is  subject  to
ebate.  ‘Watchful  waiting’  [1,2]  may  expose  the  patient
o  the  risk  of  sudden  cardiac  death,  whereas  early  AVR
s  associated  with  signiﬁcant  per-  and  postoperative  mor-
imortality  and  potential  prosthetic  valve  complications.
long  with  the  rare  case  of  severe  AS  associated  with  the
eft  ventricular  ejection  fraction  <  50%,  the  recent  Euro-
ean  Society  of  Cardiology  [2]  and  American  College  of
ardiology/American  Heart  Association  [3]  guidelines  sug-
est  the  use  of  risk  stratiﬁcation  based  on  the  prediction  of
apid  worsening  of  the  AS  and  exercise  test  results.  How-
ver,  non-speciﬁc  dyspnoea  is  frequently  observed  during
c
v
(
oxercise  testing,  and  differentiating  between  pathological
nd  physiological  breathlessness  is  sometimes  challenging.
ndeed,  aging,  a  sedentary  lifestyle,  obesity  and/or  lung
isease  complicate  the  interpretation  of  exercise  symp-
oms.
Cardiopulmonary  exercise  testing  (CPET)  has  proven
iagnostic  and  prognostic  value  in  heart  failure  and
eportedly  improves  the  quantiﬁcation  of  exercise  car-
iopulmonary  capacity  in  valve  diseases  [4,5].  Indeed,  CPET
nables  the  exhaustive,  reproducible  and  objective  quan-
iﬁcation  of  exercise  capacity  in  healthy  patients.  Several
ardiopulmonary  variables  can  be  monitored  as  a  guide  to
entilatory  and  cardiac  efﬁciencies.  Peak  oxygen  uptake
peak  VO2) was  ﬁrst  described  as  a strong  predictor  of
utcome  in  systolic  heart  failure  [6].  More  recently,  other
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CCardiopulmonary  exercise  testing  in  asymptomatic  aortic  st
ventilatory  expired  gas  variables  obtained  during  CPET  (such
as  ventilation  [VE]/carbon  dioxide  output  [VCO2]  slope)  have
been  suggested  as  severity  markers  in  heart  failure  [7].  It
was  recently  reported  that  symptom-limited  exercise  test-
ing  and  CPET  were  safe  in  asymptomatic  AS,  and  that  the
ejection  fraction  was  not  affected  [8,9].  However,  there  are
no  published  data  on  the  value  of  CPET  for  detecting  abnor-
mal  responses  to  exercise  or  the  development  of  symptoms
during  follow-up  in  patients  with  apparently  asymptomatic
AS.
Methods
Study population
Forty-three  consecutive  patients  with  no  reported  cardi-
ological  symptoms,  an  ejection  fraction  >  50%  and  severe
AS  (aortic  valve  surface  area  <  1  cm2 or  indexed  aortic
valve  surface  area  ≤  0.6  cm2/m2)  prospectively  underwent
symptom-limited  CPET.  Patients  unable  to  perform  ade-
quate  physical  exercise  and  those  with  signiﬁcant  aortic
regurgitation,  severe  mitral  regurgitation  or  stenosis  were
excluded  from  the  study.  The  physician  in  charge  of  the
patient  was  aware  of  the  results  of  the  exercise  testing
but  was  blinded  to  the  CPET  results.  Coronary  angiography
had  been  performed  in  57%  of  the  patients.  Severe  coro-
nary  artery  stenosis  was  deﬁned  as  a  reduction  of  ≥  50%
in  the  normal  diameter  of  the  left  main  coronary  artery
and  a  reduction  of  ≥  70%  in  the  right  coronary,  left  anterior
descending  and  circumﬂex  arteries.  Multivessel  coronary
artery  disease  was  deﬁned  as  signiﬁcant  stenosis  in  two
or  more  vessels.  The  study  was  approved  by  the  local
independent  ethics  committee.  All  patients  gave  their  writ-
ten  informed  consent  prior  to  participation  in  any  study
procedures.
Echocardiography
Commercially  available  ultrasound  machines  were  used  to
perform  comprehensive  echocardiography  (including  mea-
surement  of  the  aortic  valve  surface  area)  in  all  patients
[10].  Left  ventricular  ejection  fraction  was  estimated  with
Simpson’s  rule  [11].  Left  ventricle  and  left  atrium  dimen-
sions  were  measured  according  to  the  American  Society
of  Echocardiography/European  Association  of  Echocardio-
graphy  guidelines  [12].  Valvuloarterial  impedance  was
calculated  as  Zva  = (SAP  +  MPG)/SVI,  where  SAP  is  the  sys-
tolic  arterial  pressure,  MPG  is  the  mean  transaortic  pressure
gradient  and  SVI  is  the  stroke  volume  index  [13].  Left  ven-
tricular  mass  was  calculated  according  to  the  American
Society  of  Echocardiography  formula  [12]  and  normalized
against  body  surface  area.  Resting  left  ventricular  diastolic
function  was  assessed  from  the  mitral  inﬂow  (E-  and  A-wave
velocities,  the  deceleration  time  of  the  E-wave  and  the  E/A
ratio).  Early  diastolic  pulsed-wave  tissue  Doppler  annular
velocity  (e’)  at  rest  was  also  measured  at  the  septal  and  lat-
eral  side  of  the  annulus,  and  was  averaged  to  calculate  the
E/e’  ratio.  Tricuspid  valve  regurgitation  velocity  was  mea-
sured.  Pulmonary  artery  systolic  pressure  was  estimated  at
rest,  using  the  simpliﬁed  Bernoulli  equation  and  adding  an
estimated  right  atrial  pressure.
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ardiopulmonary exercise testing
ymptom-limited  CPET  was  performed  on  an  upright  cycle
rgometer  in  all  cases.  The  workload  protocol  was  chosen
o  that  maximal  effort  was  achieved  within  8—12  minutes.
xercise  workload  was  increased  by  a  ramp  protocol
20  W/min  or  10  W/min)  after  a  1-minute  warm-up  at  20  W.
atients  were  encouraged  to  exercise  to  exhaustion.  A
2-lead  electrocardiogram  (Cardiac  Assessment  System  for
xercise  Testing;  GE  Healthcare,  Waukesha,  WI,  USA)  was
ontinuously  monitored  during  exercise  and  for  at  least
 minutes  during  the  post-test  recovery  phase.  Blood  pres-
ure  was  measured  at  rest  and  every  2  minutes  during
xercise.  Patients  were  allowed  to  take  their  usual  medi-
ation  on  the  day  of  the  CPET.  Ventilatory  expired  gas  was
nalysed  with  a  Masterscreen  CPX  system  (Viasys  Health-
are,  Jaeger,  Germany),  calibrated  with  reference  gases
efore  each  test.  Breath-by-breath  gas  exchange  data  were
ecorded  and  then  averaged  over  30-second  time  periods.
eak  VO2 was  deﬁned  as  the  highest  consecutive  30-second
veraged  value  obtained  during  exercise;  it  was  normal-
zed  and  expressed  as  a  percentage  of  age-,  sex-  and  body
eight-predicted  values.  The  VE/VCO2 slope  was  calcu-
ated  by  linear  regression.  The  respiratory  exchange  ratio
RER)  was  deﬁned  as  VCO2/VO2. An  abnormal  exercise
est  (AET)  was  deﬁned  as  a  test  with:  the  occurrence  of
ymptoms,  such  as  limiting  breathlessness  or  fatigue  at
ow  workload,  angina,  dizziness  or  syncope;  an  abnormal
lood  pressure  response  (deﬁned  as  a  peak  systolic  blood
ressure  at  or  below  the  baseline  level);  or  complex  ven-
ricular  arrhythmia.  The  maximum  workload  was  recorded
nd  the  percentage  of  maximum  age-  and  sex-predicted
orkload  was  calculated  [14]. Each  patient  was  carefully
uestioned  and  observed  during  the  recovery  phase,  in  order
o  differentiate  between  abnormal  and  normal  breathless-
ess.  Abnormal  breathlessness  appeared  early  (i.e.  at  a
ow  level  of  exercise  relative  to  predicted  performance)
nd  prevented  the  patient  from  speaking  for  several  min-
tes.  Normal  breathlessness  appeared  at  an  expected  time
oint  during  CPET  and  disappeared  quickly  during  the  post-
xercise  recovery  phase.
linical follow-up
atients  were  followed  up  every  6  months  by  their  cardi-
logist  (mean  duration  of  follow-up  28  ±  31  months).  The
linical  endpoint  was  deﬁned  as  the  occurrence  of  2007
uropean  Society  of  Cardiology  guidelines  [15]  surgical  class
 triggers  (i.e.  an  AET  with  symptoms  [class  IC]  or  the
evelopment  of  cardiac  symptoms  related  to  AS  [dyspnoea,
yncope  or  angina]  during  follow-up  [class  IB]).  All  patients
eaching  the  clinical  endpoint  were  referred  for  AVR,  in
ccordance  with  the  European  Society  of  Cardiology  guide-
ines  [15].
tatistical analysis
ontinuous  variables  are  expressed  as  mean  ±  standard
eviation  and  categorical  variables  as  count  (percentage).
ntergroup  comparisons  of  categorical  variables  were  per-
ormed  with  a  chi2 test  or  Fisher’s  exact  test  (when
equired).  Student’s  t  test  or  Wilcoxon’s  rank-sum  test  were
522  F.  Levy  et  al.
Table  1  Baseline  characteristics  for  all  patients  and  comparison  between  patients  with  an  abnormal  exercise  test  with
symptoms  and  patients  with  a  normal  exercise  test.
Total  population  Abnormal  exercise  test  P
Variable  Yes  No
(n  =  43)  (n  =  12)  (n  =  31)
Age  (years)  69  ±  13  74  ±  9  67  ±  14  0.10
Men  31  (72)  9  (75)  22  (71)  0.79
Body  surface  area  (kg/m2)  1.91  ±  0.19  1.88  ±  0.12  1.92  ±  0,21  0.53
Hypertension  32  (74)  10  (83)  22  (71)  0.7
Diabetes  mellitus  10  (23)  2  (17)  8  (26)  0.7
Dyslipidaemia  19  (44)  7  (58)  12  (39)  0.24
Beta-blocker  treatment  18  (42)  6  (50)  12  (39)  0.5
Statin  treatment  20  (47)  5  (42)  15  (48)  0.69
ACE  inhibitor  treatment  26  (61)  7  (58)  19  (62)  0.86
Coronary  angiography  24  (56)  12  (100)  12  (39)  0.0001
Data are mean ± standard deviation or number (%); ACE: angiotensin-converting enzyme.
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Csed  as  appropriate  for  continuous  variables.  Receiver  oper-
ting  characteristic  (ROC)  curve  analysis  was  used  to  identify
he  best  cut-off  values  of  peak  VO2 and  VE/VCO2 slope
or  predicting  AET.  In  multivariable  analyses,  a  Cox  pro-
ortional  hazards  model  was  used  to  study  the  occurrence
f  clinical  endpoint  within  24  months  of  CPET  and  logistic
egression  was  used  to  analyse  CPET  predictors  of  AET  with
ymptoms.  In  univariate  analysis,  the  threshold  for  select-
ng  variables  for  a  multivariable  analysis  was  set  at  P  <  0.10.
urvival  curves  were  plotted  according  to  the  Kaplan—Meier
ethod  and  differences  were  tested  with  the  log-rank  test.
he  threshold  for  statistical  signiﬁcance  was  set  at  P  <  0.05.
esults
linical characteristics of the study population
nd exercise test results
he  population  comprised  of  43  consecutive  patients  (mean
ge  69  ±  13  years),  31  of  whom  were  men.  Clinical,  echocar-
iographic  and  angiographic  data  are  presented  in  Table  1.
he  mean  aortic  valve  surface  area,  mean  transvalvu-
ar  gradient  and  ejection  fraction  were  0.86  ±  0.20  cm2,
6  ±  15  mmHg  and  62  ±  7%,  respectively.  Associated  chronic
bstructive  pulmonary  disease  and  peripheral  artery  dis-
ase  were  present  in  8/44  (18%)  patients  and  1/44  (2%)
atients,  respectively.  B-type  natriuretic  peptide  and  serum
reatinine  were  available  in  25/44  (57%)  patients  and  36/44
82%)  patients,  with  mean  values  of  336  ±  47  pg/mL  and
6  ±  41  mol/L,  respectively.  The  mean  maximal  exercise
apacity  was  98  ±  38  W  (range  44—196  W).  Thirteen  (30%)
atients  had  exercised-induced  ST  depression  in  one  or
ore  leads  during  exercise.  Six  patients  had  an  ST  depres-
ion  of  ≤  1  mm  and  seven  patients  had  an  ST  depression
f  >  1 mm.  In  two  cases,  electrocardiographic  changes  were
ot  interpretable  because  of  resting  left  bundle  branch
lock.  During  exercise,  none  of  the  patients  displayed  syn-
ope  or  a  fall  in  blood  pressure  below  the  baseline.  There
ere  no  major  cardiovascular  events  during  or  after  the  test.
D
(
p
gentilatory response in patients with
bnormal exercise test
welve  (28%)  patients  stopped  the  test  because  of  the  occur-
ence  of  symptoms  (abnormal  dyspnoea  n  =  11;  angina  n  =  1);
ndication  for  AVR  was  established  in  these  12  cases.  The
emaining  31  patients  stopped  for  fatigue  or  achievement
f  maximal  heart  rate.  The  effort  was  generally  maximal,
s  32/43  (74%)  patients  achieved  an  RER  >  1.15  (mean  RER
.17  ±  0.11).  The  AETs  were  associated  with  a  signiﬁcantly
ower  percentage  of  age-predicted  maximal  heart  rate  and
xercise  maximum  workload  (Table  1).  Mean  peak  VO2 was
6.7  ±  5.0  mL/kg/min  (range  11—31  mL/kg/min).  Cardiopul-
onary  exercise  testing  showed  an  objectively  reduced
xercise  capacity  (peak  VO2 <  80%  of  predicted  value)  in
8/43  (65%)  patients.  A  peak  VO2 ≤  14  mL/kg/min  was  found
n  18/43  (42%)  patients.  ROC  curve  analysis  identiﬁed  values
or  peak  VO2 and  VE/VCO2 slope  of  14  mL/kg/min  and  34,
espectively,  as  the  best  cut-offs  for  the  prediction  of  AET
72%  and  58%  sensitivity,  75%  and  78%  speciﬁcity,  area  under
he  curve  0.76  and  0.77,  respectively)  (Figs.  1  and  2).  In
nivariate  analysis  (Tables  1  and  2),  the  four  CPET  varia-
les  signiﬁcantly  associated  with  an  AET  were  peak  VO2,
eak  VO2 ≤  14  mL/kg/min,  percentage  of  peak  VO2 pre-
icted  and  VE/VCO2 slope.  There  was  a  weak  correlation
etween  peak  VO2 and  the  VE/VCO  -  slope  (r—0.28;  P  =  0.07)
Fig.  3).  Among  the  24  patients  who  had  coronary  angiog-
aphy,  multivessel  coronary  disease  was  not  associated  with
n  AET.  In  multivariable  analysis,  VE/VCO2 slope  >  34  (hazard
atio  [HR]  5.76,  95%  conﬁdence  interval  [CI]  1.086—30.587;
 =  0.04)  and  peak  VO2 ≤  14  mL/kg/min  (HR  6.01,  95%  CI
.153—31.275;  P  =  0.03)  were  independently  associated  with
n  AET.
linical outcomeuring  follow-up,  none  of  our  patients  died  and  19/43
44%)  patients  reached  the  clinical  endpoint  (i.e.  the
ost-CPET  occurrence  of  European  Society  of  Cardiology
uidelines  surgical  class  I  triggers).  Fifteen  of  these  19  (79%)
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Table  2  Echocardiographical  and  exercise  data  from  all  patients  and  comparison  between  patients  with  an  abnormal
exercise  test  with  symptoms  and  patients  with  a  normal  exercise  test.
Total  population  Abnormal  exercise  test  P
Yes  No
(n  =  43)  (n  =  12)  (n  =  31)
Echocardiographical  data
Left  ventricular  ejection  fraction  (%)  62  ±  7  61  ±  7  63  ±  8  0.43
E/A  ratio  0.86  ±  0.20  0.82  ±  0.10  0.88  ±  0.22  0.52
E/e’  ratio  10  ±  5  10  ±  4  9  ±  6  0.81
LV  end-diastolic  diameter  (mm)  51  ±  6  50  ±  6  52  ±  7  0.58
Indexed  left  ventricular  mass  (g/m2)  134  ±  35  119  ±  45  140  ±  29  0.15
Aortic  valve  area  (cm2)  0.86  ±  0.20  0.82  ±  0.10  0.88  ±  0.23  0.25
Indexed  aortic  valve  area  (cm2/m2)  0.46  ±  0.10  0.45  ±  0.07  0.46  ±  0.11  0.73
Mean  transaortic  gradient  (mmHg)  46  ±  15  50  ±  15  45  ±  15  0.3
Pulmonary  systolic  pressure  (mmHg)  36  ±  10  41  ±  14  33  ±  7  0.12
Maximal  transaortic  velocity  (m/s)  4.3  ±  0.6  4.4  ±  0.6  4.2  ±  0.6  0.47
Valvuloarterial  impedance  (mmHg/mL/m2)  4.7  ±  1.4  4.3  ±  0.8  4.8  ±1.6  0.13
Stroke  volume  index  (mL/m2) 41  ±  15  44  ±  9  40  ±  17  0.24
Exercise  data
Maximum  workload  (W) 98  ±  38  73  ±  21  107  ±  39  0.001
Percentage  of  predicted  workload 83  ±  23 72  ±  11  87  ±  25  0.06
Percentage  of  maximal  heart  rate 83  ±  12  75  ±  11  86  ±  12  0.008
Predicted  peak  oxygen  uptake  (mL/min) 1731  ±  452 1790  ±  483  1573  ±  323  0.18
Systolic  blood  pressure  at  rest  (mmHg) 138  ±  22 133  ±  24 139  ±  21  0.42
Systolic  blood  pressure  at  peak  (mmHg) 191  ±  24 182  ±  23  194  ±  24  0.13
Respiratory  exchange  ratio 1.17  ±  0.11 1.15  ±  0.11 1.17  ±  0.11  0.62
Respiratory  exchange  ratio  <  1.15 6  (14) 2  (17) 4  (13) 0.66
Peak  VO2 (mL/kg/min) 16.7  ±  5.0 13.8  ±  2.5 17.8  ±  5.3  0.002
Peak  VO2 ≤  14  mL/kg/min 18  (42) 9  (75) 9  (29) 0.006
Percentage  of  predicted  peak  VO2 (%)  77  ±  14  67  ±  7  80  ±  15  0.0001
Oxygen  pulse  (mL/beat)  11.1  ±  2.8  10.4  ±  2.2  11.3  ±  3.0  0.4
Peak  VE/VCO2 33  ±  7  37  ±  9  32  ±  6  0.09
VE/VCO2 slope  32  ±  7  37  ±  8  31  ±  6  0.017
VE/VCO2 slope  >  34  11  (26)  6  (50)  5  (16)  0.02
Data are mean ± standard deviation or number (%); VCO2: carbon dioxide output; VE: ventilation; VO2: oxygen uptake.
Table  3  Baseline  characteristics  for  all  patients  and  predictors  of  reaching  the  clinical  endpoint  in  univariate  analysis.
Total  population  Clinical  endpoint  P
Variable  Yes  No
(n  =  43)  (n  =  19)  (n  =  24)
Age  (years)  69  ±  13  72  ±  11  67  ±  15  0.27
Men  31  (72)  14  (74)  17  (71)  0.83
Body  surface  area  (kg/m2)  1.91  ±  0.19  1.90  ±  0.22  1.93  ±  0.14  0.6
Hypertension  32  (74)  15  (71)  17  (79)  0.54
Diabetes  mellitus  10  (23)  3  (16)  7  (29)  0.3
Dyslipidaemia  19  (44)  8  (42)  10  (42)  0.8
Beta-blocker  treatment  18  (42)  8  (42)  10  (42)  0.97
Statin  treatment  20  (47)  12  (63)  8  (33)  0.6
ACE  inhibitor  treatment  26  (61)  12  (63)  14  (58)  0.74
Coronary  angiography  24  (56)  18  (95)  6  (25)  0.0001
Data are mean ± standard deviation or number (%); ACE: angiotensin-converting enzyme.
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Table  4  Echocardiographical  and  exercise  data  from  all  patients  and  predictors  of  reaching  the  clinical  endpoint  in
univariate  analysis.
Total  population  Clinical  endpoint  P
Variable  Yes  No
(n  =  43)  (n  =  19)  (n  =  24)
Echocardiographic  data
Left  ventricular  ejection  fraction  (%)  62  ±  7  61  ±  6  64  ±  9  0.21
E/A  ratio  0.86  ±  0.20  0.78  ±  0.25  0.95  ±  0.74  0.41
E/e’  ratio  10  ±  5  10  ±  4  10  ±  6  0.98
Left  ventricular  end-diastolic  diameter  (mm)  51  ±  6  53  ±  6  50  ±  6  0.1
Left  ventricular  end-systolic  diameter  (mm)  32  ±  7  35  ±  7  30  ±  7  0.05
Indexed  left  ventricular  mass  (g/m2) 134  ±  35  135  ±  41  133  ±  30  0.88
Aortic  valve  area  (cm2)  0.86  ±  0.20  0.80  ±  0.15  0.91  ±  0.22  0.06
Indexed  aortic  valve  area  (cm2/m2)  0.46  ±  0.10  0.42  ±  0.08  0.49  ±  0.10  0.03
Mean  transaortic  gradient  (mmHg)  46  ±  15  50  ±  16  43  ±  13  0.13
Pulmonary  systolic  pressure  (mmHg)  36  ±  10  37  ±  12  34  ±  8  0.37
Maximal  transaortic  velocity  (m/s)  4.3  ±  0.6  4.4  ±  0.6  4.2  ±  0.5  0.28
Valvuloarterial  impedance  (mmHg/mL/m2) 4.7  ±  1.4  4.8  ±  1.5  4.5  ±  1.3  0.6
Stroke  volume  index  (mL/m2)  41  ±  15  41  ±  12  41  ±  18  0.96
Exercise  data
Maximum  workload  (W) 98  ±  38 91 ±  35  103  ±  40  0.34
Percentage  of  predicted  workload  (%) 83  ±  23  78  ±  14  89  ±  30  0.15
Percentage  of  maximal  heart  rate 83  ±  12 82 ±  10  83  ±  15  0.77
Predicted  peak  oxygen  uptake  (mL/min) 1731  ±  452 1717  ±  403 1784  ±  525  0.53
Systolic  blood  pressure  at  rest  (mmHg) 138  ±  22 130 ±  27  143  ±  24  0.05
Systolic  blood  pressure  at  peak  (mmHg) 191  ±  24 190 ±  24 192  ±  24  0.86
Respiratory  exchange  ratio 1.17  ±  0.11 1.14  ±  0.11 1.19  ±  0.12 0.17
Respiratory  exchange  ratio  <  1.15 6  (14) 4 (21) 2  (8)  0.4
Peak  VO2 (mL/kg/min) 16.7  ±  5.0 16.2  ±  5.6 17.1  ±  4.5 0.52
Peak  VO2 ≤  14  mL/kg/min  18  (42)  11  (57)  7  (29)  0.037
Percentage  of  predicted  peak  VO2 (%)  77  ±  14  75  ±  12  78  ±  16  0.85
Oxygen  pulse  (mL/beat)  11.1  ±  2.8  10.7  ±  2.3  11.3  ±  3.2  0.47
Peak  VE/VCO2 33  ±  7  36  ±  8  31  ±  5  0.02
VE/VCO2 slope  32  ±  7  35  ±  8  30  ±  6  0.005
VE/VCO2 slope  >  34  11  (26)  9  (47)  2  (8)  0.004
Data are mean ± standard deviation or number (%); VCO : carbon dioxide output; VE: ventilation; VO : peak oxygen uptake.
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atients  underwent  AVR  within  a  year  of  CPET.  In  univari-
te  analysis  (Tables  3  and  4),  indexed  aortic  valve  surface
rea  (P  =  0.03),  peak  VO2 ≤  14  mL/kg/min  (P  =  0.037)  and
E/VCO2 slope  >  34  (P  =  0.004)  were  predictive  of  reaching
he  clinical  endpoint  (Figs.  4  and  5).  In  multivariable  anal-
sis,  VE/VCO2 slope  >  34  (HR  3.681,  95%  CI  1.318—10.286;
 =  0.013)  and  peak  VO2 ≤  14  mL/kg/min  (HR  3.058,  95%  CI
.074—8.713;  P  =  0.036)  were  predictors  of  reaching  the
linical  endpoint.  Eleven  of  the  12  patients  with  an  AET
nderwent  AVR  an  average  of  2.6  ±  3.3  months  after  CPET;
ne  patient  declined  surgery.  Four  patients  developed  symp-
oms  (syncope  and  dyspnoea)  and  underwent  AVR  during
ollow-up  (actually  >  12  months  after  CPET;  mean  time  inter-
al  21  ±  4  months).iscussion
his  is  the  ﬁrst  study  to  describe  the  value  of  CPET  in  clin-
cal  practice  for  the  management  of  asymptomatic  AS  —  a
d
a
i
m2
omplex  issue  in  heart  valve  disease.  Our  results  suggest  that
PET  can  accurately  detect  false  asymptomatic  patients  and
atients  likely  to  develop  symptoms.  Studies  in  larger  series
re  needed  to  conﬁrm  the  prognostic  value  of  this  inexpen-
ive  test,  which  is  routinely  available.
isk stratiﬁcation in asymptomatic aortic
tenosis
atients  with  asymptomatic  severe  AS  may  remain  symptom-
ree  for  a  long  time.  The  annual  risk  of  sudden  cardiac  death
s  relatively  low,  at  around  0.4%  per  year  [3]. In  a  recent
arge  study  of  622  asymptomatic  patients  with  severe  AS
deﬁned  as  a peak  transaortic  velocity  ≥  4  m/s),  the  annual
isk  of  cardiac  sudden  death  was  1%  [1],  with  a  particularly
levated  risk  just  after  symptom  onset.  Indeed,  all  the  sud-
en  deaths  in  the  series  studied  by  Pellika  et  al.  [1]  occurred
 few  weeks  after  the  development  of  symptoms.  CPET  may
mprove  the  risk  stratiﬁcation  for  sudden  death.  A  recent
eta-analysis  showed  that  the  risk  of  cardiac  death  was
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Figure 3. Correlation between ventilation/carbon dioxide out-
put (VE/VCO2) slope and peak oxygen uptake (peak VO2) for all
43 patients. The vertical dotted line indicates peak VO2 threshold of
14 mL/kg/min; the horizontal dotted line indicates VE/VCO2 thresh-
old of 34; represents the 12 patients with an abnormal exercise
test; represents the 31 patients with a normal exercise test.Figure 1. Receiver operating characteristic curve of peak oxygen
uptake (peak VO2) to predict abnormal exercise test.
higher  in  patients  with  an  AET  than  in  patients  with  a  nor-
mal  exercise  test  result  (5%  vs.  0%,  respectively)  [16].  In
the  present  series,  none  of  the  unoperated  patients  with  no
symptoms  during  the  CPET  died  suddenly  during  the  follow-
up  period.  Thus,  ‘watchful  waiting’  [1,2]  may  be  associated
with  a  low  risk  of  sudden  cardiac  death,  whereas  early  AVR
in  asymptomatic  AS  is  associated  with  signiﬁcant  per-  and
postoperative  morbimortality  and  potential  prosthetic  valve
complications.  According  to  the  current  European  Society
Figure 2. Receiver operating characteristic curve of ventila-
tion/carbon dioxide output (VE/VCO2) slope to predict abnormal
exercise test.
Figure 4. Kaplan—Meier plot illustrating overall survival without
reaching the clinical endpoint (occurrence of European Society of
Cardiology guidelines surgical class I triggers) in the 43 patients with
asymptomatic aortic stenosis in our series. Patients are stratiﬁed
according to peak oxygen uptake (peak VO2) ≤ or > 14 mL/kg/min.
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Figure 5. Kaplan-Meier plot illustrating overall survival without
reaching the clinical endpoint (occurrence of European Society of
Cardiology guidelines surgical class I triggers) in the 43 patients
with asymptomatic aortic stenosis in our series. Patients are strat-
iﬁed according to ventilation/carbon dioxide output (VE/VCO2)
s
o
s
d
s
w
r
p
l
m
a
c
0
t
f
t
a
a
t
h
d
E
s
T
t
a
r
t
l
p
l
b
a
B
u
2
v
i
D
o
s
o
e
i
w
[
d
t
t
m
n
t
o
t
t
d
a
i
V
c
P
a
a
b
3
w
t
a
l
a
r
o
l
t
i
I
s
r
e
t
h
s
a
Vlope ≤ or > 34.
f  Cardiology  guidelines,  risk  stratiﬁcation  in  asymptomatic
evere  AS  is  based  on  the  ejection  fraction  at  rest  and
uring  exercise,  and  on  the  risk  of  progression  of  the  steno-
is.  Early  surgery  is  indeed  indicated  in  the  few  patients
ith  asymptomatic  AS  and  depressed  ejection  fraction  at
est  and  in  patients  with  an  AET  (particularly  those  dis-
laying  symptoms)  [2].  Hence,  AVR  should  be  considered  in
ow-operative-risk  patients  and  also  in  patients  with  nor-
al  exercise  performance  but  very  severe  AS  (deﬁned  as
 peak  transvalvular  velocity  >  5.5  m/s  or  severe  valve  cal-
iﬁcation  and  peak  transvalvular  velocity  progression  of  ≥
.3  m/s  per  year  [class  IIaC]).  Several  studies  have  shown
he  superiority  of  exercise  testing  over  echocardiography
or  the  prediction  of  clinical  events  [17,18].  Nevertheless,
he  symptoms  observed  during  exercise  in  elderly  individuals
re  often  equivocal.  The  key  point  is  to  be  able  to  differenti-
te  between  normal  and  abnormal  breathlessness.  It  is  clear
hat  CPET  provides  more  information  on  ventilatory  and
aemodynamic  variables  than  conventional  exercise  testing
oes.
xercise testing in asymptomatic aortic
tenosishe  safety  of  exercise  testing  [16]  and  CPET  [8,9]  in  asymp-
omatic  AS  was  recently  studied  in  a  large  series.  No  major
dverse  events  during  or  after  the  test  were  reported.  The
i
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ate  of  minor  rhythm  disorder  events  (3—5  beats  with  ven-
ricular  tachycardia  or  paroxysmal  atrial  ﬁbrillation)  was
ow  (4%  and  1%,  respectively)  [8].  Likewise,  none  of  our
atients  displayed  severe  symptoms  or  major  cardiovascu-
ar  events  during  or  after  the  test.  Nevertheless,  CPET  must
e  performed  with  caution  and  appropriate  supervision,
nd  the  protocol  should  be  less  intense  than  the  standard
ruce  protocol  (especially  in  elderly  or  untrained  individ-
als).  In  our  study,  symptoms  were  revealed  by  CPET  in
7%  of  the  patients  with  apparently  asymptomatic  AS;  this
alue  is  consistent  with  the  literature  data  (AET  rates  rang-
ng  from  26%  to  37%,  depending  on  the  series)  [5,18,19].
yspnoea  is  the  most  frequent  cause  of  an  AET  (92%  in
ur  study,  81%  in  a  study  by  Olaf  et  al.  [5]  and  61%  in  a
tudy  by  Das  et  al.  [18]).  Characterizing  dyspnoea  as  normal
r  abnormal  is  sometimes  problematic  —  especially  in  the
lderly.  Indeed,  a  great  majority  of  patients  with  exercise-
nduced  dizziness  subsequently  develop  cardiac  symptoms,
hereas  only  half  of  those  with  limiting  breathlessness  do  so
5,18—21]. The  positive  predictive  value  of  exercise-induced
yspnoea  was  greater  for  patients  aged  <  70  years  than  for
he  study  population  as  a  whole  (79%  vs.  57%,  respec-
ively  [20]). Thus,  the  deﬁnition  of  abnormal  breathlessness
ay  appear  to  be  subjective.  More  objective  criteria  are
eeded  to  specify  the  pathological  nature  of  the  symp-
oms.  CPET  has  proven  ability  to  characterize  the  etiology
f  exercise  intolerance  and  unexplained  dyspnoea  [22].  The
est  result  reﬂects  performance  capacity  and  the  ability  of
he  heart,  lungs,  vasculature  and  blood  to  sustain  oxygen
elivery  and  carbon  dioxide  removal  [22]. However,  there
re  very  few  published  data  on  the  speciﬁc  value  of  CPET
n  asymptomatic  AS.  Clyne  et  al.  [23]  showed  that  peak
O2 was  lower  in  patients  with  asymptomatic  AS  than  in
ontrols  (26.7  ±  6.3  vs.  36.3  ±  9.5  mL/kg/min,  respectively;
 =  0.004).  In  the  present  study,  peak  VO2 ≤  14  mL/kg/min
nd  VE/VCO2 slope  >  34  were  independently  associated  with
n  AET.  In  contrast,  none  of  the  echocardiographic  varia-
les  predicted  AET.  These  cut-off  values  (14  mL/kg/min  and
4)  have  been  widely  used  in  studies  of  heart  failure  [6].  It
as  shown  recently  [21], using  the  Innocor® device,  that
he  occurrence  of  symptoms  during  treadmill  exercise  in
pparently  asymptomatic  AS  patients  was  associated  with
ower  peak  VO2. However,  the  Innocor® device  is  not  widely
vailable.  Although  oxygen  pulse  is  considered  as  a  cor-
elate  to  stroke  volume  at  exercise,  we  did  not  identify
xygen  pulse  as  a  predictor  of  AET,  probably  because  of  the
arge  number  of  patients  in  our  series  under  beta-blocker
herapy.  The  present  study  shows  the  role  of  ventilatory
nsufﬁciency  in  the  context  of  apparently  asymptomatic  AS.
ndeed,  peak  VO2 might  be  underestimated  if  exercise  is
topped  early  because  of  low  patient  motivation  [24].  It  was
ecently  demonstrated  that  the  assessment  of  ventilatory
fﬁciency  (measured  as  the  relationship  between  ventila-
ion  and  carbon  dioxide  production  [i.e.  the  VE/VCO2 slope])
as  prognostic  value  in  heart  failure  [7,24].  The  VE/VCO2
lope  can  be  derived  from  submaximal  exercise  test  results
nd  is  independent  of  the  patient’s  level  of  motivation.  The
E/VCO2 slope  provides  independent  prognostic  information
n  addition  to  peak  VO2 and  is  closely  related  to  symptoms
25]. Many  factors  inﬂuence  the  VE/VCO2 slope,  including
eripheral  ergoreceptor  response,  the  muscle  mass  used  in
he  exercise,  elevated  ventilation/perfusion  mismatch  and
enos
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pulmonary  vascular  resistance  [26].  An  abnormal  VE/VCO2
slope  in  chronic  heart  failure  can  be  explained  by  abnormal
pulmonary  perfusion  [27]  as  a  result  of  an  impaired  cardiac
output  response  to  exercise,  which  in  turn  increases  mis-
match  between  ventilation  and  lung  perfusion.  However,
one  should  bear  in  mind  that  the  presence  of  any  signiﬁ-
cant  respiratory  disease  will  inﬂuence  the  VE/VCO2 slope.  A
recent  study  [21]  elegantly  reported  a  fall  in  peak  cardiac
index  in  apparently  asymptomatic  AS  patients  with  an  AET.
Maréchaux  et  al.  [28]  showed  that  a  fall  in  ejection  fraction
during  exercise  increased  the  risk  of  developing  symptoms
in  previously  asymptomatic  AS.  These  data  are  consistent
with  our  results  and  suggest  that  there  is  a  limited  rise  in
cardiac  output  during  exercise,  which  leads  to  a  lower  peak
VO2,  impaired  ventilatory  efﬁciency  and  indeed  pathologi-
cal  dyspnoea  during  exercise.  Patients  with  severe  AS  may
overestimate  their  actual  exercise  capacity,  as  they  gradu-
ally  reduce  their  activity  to  avoid  symptoms.  In  our  study,
66%  of  the  participants  showed  an  abnormally  low  exer-
cise  capacity  (based  on  the  percentage  of  predicted  peak
VO2).
Study limitations
In  our  study,  we  did  not  use  a  Borg  Scale  to  document  patient
exertion,  which  may  help  to  better  discriminate  between
abnormal  and  normal  breathlessness.  Coronary  angiogra-
phy  was  performed  in  57%  of  our  patients  (in  the  event
of  angina  or  in  patients  referred  to  us  for  AVR).  Serial
CPET  might  increase  patient  motivation  and  thereby  reduce
the  number  of  patients  with  RER  <  1.15  at  peak  exercise.
Submaximal  exercise  because  of  a  lack  of  patient  moti-
vation  inﬂuences  CPET  results  dramatically.  Nevertheless,
only  4  (14%)  patients  did  not  achieve  an  RER  >  1.15  in  our
series.  An  RER  <  1.15  was  not  associated  with  AET  or  with
reaching  the  clinical  endpoint.  Serial  CPET  might  also  be
useful  for  detecting  a  decline  in  functional  capacity  or
ventilatory  efﬁciency  during  long-term  follow-up  of  asymp-
tomatic  patients.  Only  6/23  (26%)  unoperated  patients
in  our  series  had  undergone  serial  CPET.  Given  the  rel-
atively  small  sample  size,  the  results  of  this  pilot  study
need  to  be  conﬁrmed  in  large  studies.  Further  research
should  speciﬁcally  evaluate  the  incremental  value  of  CPET
over  standard  exercise  test  in  a  large  cohort  of  asymp-
tomatic  patients  with  severe  AS  and  a  normal  exercise
test.
Conclusion
Conventional  risk  stratiﬁcation  of  asymptomatic  severe
AS  is  mainly  based  on  the  results  of  exercise  test-
ing.  Peak  VO2 ≤  14  mL/kg/min  and  VE/VCO2 slope  >  34
were  associated  with  the  observation  of  symptoms  dur-
ing  conventional  exercise  testing  and  the  occurrence  of
European  Society  of  Cardiology  guidelines  surgical  class
I  triggers.  Careful  follow-up  is  fundamental  in  asymp-
tomatic  patients  with  severe  AS.  CPET  appears  to  be  useful
for  this  follow-up,  in  order  to  reveal  under-reported  or
underestimated  symptoms  and  to  predict  the  short-term
occurrence  of  symptoms  in  truly  asymptomatic  individu-
als.
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